Biocardia Inc (BCDA) Stock Price, Quote & News

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 226 0120

Fax: 650 631 3731

Website: www.biocardia.com

Address:

320 Soquel Way, Sunnyvale, United States

Raycloser Oct. 24 at 10:37 PM

$BCDA why the after hours drop? Anyone?

1 · Reply

EZ_Money11 Oct. 24 at 9:43 PM

$BCDA almost 6k shares now! 💰💰💰

0 · Reply

chris_stocks Oct. 24 at 8:57 PM

$BCDA Anyone know why the SP went down?

1 · Reply

chris_stocks Oct. 23 at 11:01 PM

$BCDA Not sure why you think it'll be $40 one day. The highest anyone has for this is $25. Although, I like your PT a lot better. lol

1 · Reply

SamuraiX7 Oct. 23 at 7:14 PM

$BCDA added

0 · Reply

Tom678 Oct. 23 at 5:06 PM

$BCDA agree 👍

0 · Reply

canievas Oct. 23 at 4:39 PM

$BCDA GREAT OPPORTUNITY TO BUY. BUYING MORE THIS IS MY VERY LONG TERM GEM ONE DAY SHE WILL BE OVER $40. For sure. Buy and hold with patience 💎🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

Bedroom_trader Oct. 22 at 3:50 PM

$BCDA Hopefully Peter Altman isn’t just planning to run away with his cash warrants. They need to time this correctly with the state of the market and get moving. Such strong potential but I’m losing confidence.

1 · Reply

StockInsanity2025 Oct. 22 at 3:41 PM

$BCDA does anyone know if there's any news upcoming besides the FDA meeting? How long after FDA meeting does it take to get approved? Does anyone forsee this going up a dollar before the end of year? 🤔

1 · Reply

chris_stocks Oct. 21 at 4:21 PM

$BCDA pump it for all it's worth¡!!!!!!!. My 1720 shares want to grow into $5 shares!!!!

1 · Reply

BioCardia Regains Compliance with Nasdaq Listing Requirements

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 7:00 AM EDT - 5 weeks ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 4, 2025, 9:00 AM EDT - 7 weeks ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Aug 11, 2025, 8:37 PM EDT - 2 months ago

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 9:15 AM EDT - 2 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 6, 2025, 3:18 PM EDT - 2 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 4, 2025, 6:00 AM EDT - 2 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

May 21, 2025, 8:30 AM EDT - 5 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 14, 2025, 7:40 PM EDT - 5 months ago

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 5 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 9, 2025, 4:28 PM EDT - 6 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Apr 11, 2025, 9:15 AM EDT - 7 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 11:30 PM EDT - 7 months ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 1:39 PM EDT - 7 months ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 7 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 7 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 8 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 8 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 9 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 9 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 11 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Nov 13, 2024, 7:49 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 7:53 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Mar 27, 2024, 8:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:00 PM EDT - 1 year ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 1 year ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 1 year ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 8, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Jan 31, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 18, 2023, 7:16 AM EST - 2 years ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Nov 29, 2023, 7:00 AM EST - 2 years ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 16, 2023, 12:56 PM EST - 2 years ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Raycloser Oct. 24 at 10:37 PM

$BCDA why the after hours drop? Anyone?

1 · Reply

EZ_Money11 Oct. 24 at 9:43 PM

$BCDA almost 6k shares now! 💰💰💰

0 · Reply

chris_stocks Oct. 24 at 8:57 PM

$BCDA Anyone know why the SP went down?

1 · Reply

chris_stocks Oct. 23 at 11:01 PM

$BCDA Not sure why you think it'll be $40 one day. The highest anyone has for this is $25. Although, I like your PT a lot better. lol

1 · Reply

SamuraiX7 Oct. 23 at 7:14 PM

$BCDA added

0 · Reply

Tom678 Oct. 23 at 5:06 PM

$BCDA agree 👍

0 · Reply

canievas Oct. 23 at 4:39 PM

0 · Reply

Bedroom_trader Oct. 22 at 3:50 PM

1 · Reply

StockInsanity2025 Oct. 22 at 3:41 PM

1 · Reply

chris_stocks Oct. 21 at 4:21 PM

$BCDA pump it for all it's worth¡!!!!!!!. My 1720 shares want to grow into $5 shares!!!!

1 · Reply

SamuraiX7 Oct. 21 at 3:33 PM

$BCDA something big brewing

1 · Reply

Tom678 Oct. 21 at 2:07 PM

$BCDA

0 · Reply

SidneyRittinger147 Oct. 17 at 3:36 PM

$BCDA scaling heart treatments as AITX scales automation — 23 units and 17 software licenses in one day show unmatched execution speed.

0 · Reply

chris_stocks Oct. 16 at 9:48 PM

$BCDA Since this company is meeting with the FDA in Q4 to discuss a path forward to approval for CardiAmp, does anyone know about how long the approval process would take?

1 · Reply

chris_stocks Oct. 16 at 7:19 PM

$BCDA I'm back, bitchessssssssssss!!!!!!!!!!!!! I just bought 1720 shares. Let's get the pump going!

1 · Reply

EZ_Money11 Oct. 16 at 5:45 PM

$BCDA slap the ask over $2 and watch the volume flow in!

0 · Reply

SWCtrader Oct. 16 at 5:11 PM

$BCDA come one give me something god damnit

1 · Reply

StockInsanity2025 Oct. 15 at 5:22 PM

$BCDA hopefully 1.51 is a good entry point...

1 · Reply

SWCtrader Oct. 15 at 5:21 PM

$BCDA need a little PR now

0 · Reply

chris_stocks Oct. 15 at 4:52 PM

$CHAI BTW, you may all want to check out $BCDA. They are in Phase 3 and are scheduled to meet with the FDA in Q4 to see about their product getting approval. It's TP is $25. NFA!!!! I thought CHAI would have been a great investment, but look where we are, so clearly I'm not the best person to listen to regarding stocks. Do your own DD.

1 · Reply

chris_stocks Oct. 15 at 4:44 PM

$CHAI I might bounce out of here today. Gonna wait and see what AH does, if anything (probably won't do a damn thing). I want to buy more $BCDA shares, and with the direction CHAI is going, this is a complete loser not likely to rebound at all. But I'll see.

0 · Reply

Baddb Oct. 15 at 3:28 PM

$BCDA I feel we gonna wake up 1 morning and this will be a 5 to 6 dollar gap up in pm 😜✌️

1 · Reply

Market Cap	8.10M
Revenue (ttm)	60,000.00
Net Income (ttm)	-7.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,250.00%
Debt to Equity Ratio	0.00

Volume	104,100
Avg Vol	716,286
Day's Range	N/A - N/A
Shares Out	5.81M
Stochastic %K	17%
Beta	0.80
Analysts	Sell
Price Target	$15.50